-
NCCU 2025 | When Urologic Surgery Meets the Wave of Innovation: Technology, Clinical Practice, and Young Talent Development Drive the Field Forward
Editor’s Note: In recent years, the incidence of urologic cancers in China has continued to rise, with prostate, bladder, and kidney cancers now among the most common malignancies nationwide—posing a…
-
Adv Sci | MARCO⁺ Tumor-Associated Macrophages Drive Immunotherapy Resistance in Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most common subtype of kidney cancer and continues to rise in incidence worldwide. RCC is also regarded as one of the most immune- and…
-
NCCU 2025 | Prof. Sujun Han: Enhancing Outcomes in Urologic Oncology Through Quality Control and Emerging Therapeutic Strategies
Editor’s Note: In recent years, the incidence of urologic malignancies in China has continued to rise, with prostate, bladder, and kidney cancers now ranking among the most common tumors nationwide…
-
NCCU 2025 | Prof. Peter Hammerer Discusses Precision Surgery and Radiotherapy Decision-Making in Oligometastatic Prostate Cancer
Editor’s Note: Oligometastatic prostate cancer occupies a unique clinical space—it is neither confined entirely to the prostate nor widely metastatic throughout the body. This intermediate state presents distinct therapeutic challenges…
-
NCCU 2025 | Professor Yong Zhang Explains the Advantages, Beneficiaries, and Learning Path of the “Xing’s Neobladder” Technique
Bladder cancer is one of the most common malignancies of the urinary system. Radical cystectomy remains one of the standard treatments, and urinary diversion is a crucial component of this complex procedure.Professor Xing Nianzeng and his team pioneered a novel laparoscopic-friendly orthotopic ileal neobladder reconstruction technique, known as the “Xing’s Neobladder.” This innovative approach utilizes…
-
Navigating Global Access, Regulatory Harmonization, and Future Directions in CAR-T Cell Therapy: Insights from a Global Panel Discussion
The Cellular Therapy and Immunotherapy Conference 2025 was successfully held in Hangzhou, China, from November 13-16, 2025. The conference brought together a distinguished gathering of the world’s leading researchers, clinicians, and industry pioneers to share groundbreaking advancements and foster collaboration in the rapidly advancing fields of cellular and immune-based treatments. The morning’s agenda offered a…
-
Prof. Jae-Ho Yoon: Korea’s ALL Management in the Era of Gene Analysis and Targeted Immunotherapy
At the conference, Professor Jae-Ho Yoon from Seoul St. Mary’s Hospital delivered an outstanding presentation titled “Diagnostic and Therapeutic Advances in Korea with Acute Lymphoblastic Leukemia in the Era of…
Connecting Medical Expertise through Media